P781: CLINICAL OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION (HCRU) IN PATIENTS WITH LR-MDS REINITIATING ESAS FOLLOWING PREVIOUS ESA TREATMENT
Main Authors: | G. Garcia-Manero, R. K. Matsuno, A. McBride, T. D. Brown, D. Idryo, R. Broome, A. Herriman, T. Johnson, K. Wilkinson, S. Walters, A. Schrag, C. Johanson, M. Izano, S. Mukherjee |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000846008.60144.6a |
Similar Items
ESA 243-3 - AERODINAMIK OKT 04.
by: PPKA, Pusat Pengajian Kejuruteraan Aeroangkasa
Published: (2004)
by: PPKA, Pusat Pengajian Kejuruteraan Aeroangkasa
Published: (2004)
Similar Items
-
PB1926: REAL-WORLD ERYTHROPOIESIS-STIMULATING AGENT (ESA) TREATMENT PATTERNS AND OUTCOMES AMONG US PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)
by: S. Mukherjee, et al.
Published: (2022-06-01) -
EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
by: G. Garcia-Manero, et al.
Published: (2024-01-01) -
PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS
by: Guillermo Garcia-Manero, et al.
Published: (2023-08-01) -
S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
by: Matteo Giovanni Della Porta, et al.
Published: (2023-08-01) -
ESA's Planetary Program.
by: Taylor, F
Published: (1994)